Proteomics

Applications and opportunities in preclinical drug development

Sandra Steiner, Frank Witzmann

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.

Original languageEnglish
Pages (from-to)2099-2104
Number of pages6
JournalElectrophoresis
Volume21
Issue number11
DOIs
StatePublished - 2000

Fingerprint

Proteomics
Availability
Pharmaceutical Preparations
Public Sector
Genomics
DNA Sequence Analysis
Genes
Throughput
Clinical Trials
Genome
Safety
DNA

Keywords

  • Functional genomics
  • Mass spectrometry
  • Pharmaceutical development
  • Proteomics
  • Review
  • Two-dimensional electrophoresis

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Proteomics : Applications and opportunities in preclinical drug development. / Steiner, Sandra; Witzmann, Frank.

In: Electrophoresis, Vol. 21, No. 11, 2000, p. 2099-2104.

Research output: Contribution to journalArticle

@article{1e301f1c394b48eeb0569c4f95fa8448,
title = "Proteomics: Applications and opportunities in preclinical drug development",
abstract = "Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.",
keywords = "Functional genomics, Mass spectrometry, Pharmaceutical development, Proteomics, Review, Two-dimensional electrophoresis",
author = "Sandra Steiner and Frank Witzmann",
year = "2000",
doi = "10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N",
language = "English",
volume = "21",
pages = "2099--2104",
journal = "Electrophoresis",
issn = "0173-0835",
publisher = "Wiley-VCH Verlag",
number = "11",

}

TY - JOUR

T1 - Proteomics

T2 - Applications and opportunities in preclinical drug development

AU - Steiner, Sandra

AU - Witzmann, Frank

PY - 2000

Y1 - 2000

N2 - Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.

AB - Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.

KW - Functional genomics

KW - Mass spectrometry

KW - Pharmaceutical development

KW - Proteomics

KW - Review

KW - Two-dimensional electrophoresis

UR - http://www.scopus.com/inward/record.url?scp=0033919787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033919787&partnerID=8YFLogxK

U2 - 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N

DO - 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N

M3 - Article

VL - 21

SP - 2099

EP - 2104

JO - Electrophoresis

JF - Electrophoresis

SN - 0173-0835

IS - 11

ER -